NASDAQ · ASND
Ascendis Pharma A/S Ordinary Share financials
$228.07−0.86%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|
| Revenue | $62.4M | $37.8M | $14.2M |
| Gross profit | $62.4M | $37.8M | $14.2M |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Operating income | -$79.5M | -$80.7M | -$72.8M |
| Net income | -$95.5M | -$70.1M | -$71.6M |
| Net margin | −153.2% | −185.4% | −504.1% |
| Diluted EPS | $-0.16 | $-0.13 | $-0.17 |
| EBITDA | -$71.7M | -$75.2M | -$69.5M |
| Operating cash flow | -$104.4M | -$54.3M | -$48.2M |
| Free cash flow | -$108.3M | -$79.0M | -$59.7M |
| Diluted shares | 584.3M | 527.6M | 424.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $68.4M | $84.0M | $158.8M |
| Short-term investments | $136.8M | $124.2M | $22.7M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $276.7M | $281.1M | $234.5M |
| Total liabilities | $29.9M | $78.2M | $68.4M |
| Shareholders' equity | $246.9M | $203.0M | $166.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology